VHCP Management, LLC

Q4 2016 13F Holdings

  • Location
    new york, NY
  • Num holdings

    21

  • Value ($000)

    $92,999

  • Date Filed
    02/13/2017
  • Form type
    13F-HR
  • CIK
    0001479355
  • All SEC filings
  • Note
    Holdings aggregated across “other managers” listed in original SEC filing, see here for detailed holdings broken out by other managers
Compare Q4 2016 to
Select Quarter
Issuer Name
Class
CUSIP
VALUE
%
Shares
Principal
Option Type
---

DBV Technologies

COM
F2927N109
$31.13M
34 %

456,893

A
AXD2

Heron Therapeutics Inc

COM
427746102
$14.35M
15 %

1,095,734

C
CHRS

Coherus Biosciences Inc

COM
19249H103
$8.60M
9 %

305,505

B
BCRX

BioCryst Pharmaceuticals Inc

COM
09058V103
$7.31M
8 %

1,155,104

F
FLML

Avadel Pharmaceuticals

COM
338488109
$5.20M
6 %

500,000

R
RARX

Ra Pharmaceuticals

COM
74933V108
$3.53M
4 %

232,500

A
ADVM

Adverum Biotechnologies

COM
00773U108
$3.20M
3 %

1,102,735

L
LPCNEUR

Lipocine Inc

COM
53630X104
$3.13M
3 %

849,921

C
CLCD

CoLucid Pharmaceuticals

COM
19716T101
$2.48M
3 %

68,190

---

Axovant Sciences Ltd

COM
G0750W104
$2.29M
3 %

184,110

Rows Per Page
10
  • 10
  • 50
  • 100
1 - 10 of 21